All Stories

  1. Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study

    Article • Diabetes Metabolic Syndrome and Obesity, July 2015, Taylor & Francis

    Dr Sylvie Dejager

  2. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database

    Article • Vascular Health and Risk Management, July 2015, Dove Medical Press

    Dr Sylvie Dejager

  3. Physical activity in patients with type 2 diabetes and hypertension – insights into motivations and barriers from the MOBILE study

    Article • Vascular Health and Risk Management, June 2015, Taylor & Francis

    Dr Sylvie Dejager, Mr Stéphane Quéré

  4. “Mild dysglycemia” in type 2 diabetes: to be neglected or not?

    Article • Journal of Diabetes and its Complications, April 2015, Elsevier

    Dr Sylvie Dejager

  5. The dawn phenomenon in type 2 diabetes: How to assess it in clinical practice?

    Article • Diabetes & Metabolism, April 2015, Elsevier

    Dr Sylvie Dejager

  6. Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

    Article • Diabetes Therapy, September 2014, Springer Science + Business Media

    Dr Sylvie Dejager

  7. Response to Comment on Monnier et al. Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes: Is This of Concern? Diabetes Care 2013;36:4057–4062

    Article • Diabetes Care, June 2014, American Diabetes Association

    Dr Sylvie Dejager

  8. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study

    Article • Vascular Health and Risk Management, June 2014, Taylor & Francis

    Mr Stéphane Quéré, Dr Sylvie Dejager

  9. Residual dysglycemia when at target HbA1c of 7% (53mmol/mol) in persons with type 2 diabetes

    Article • Diabetes Research and Clinical Practice, June 2014, Elsevier

    Dr Sylvie Dejager

  10. Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study

    Article • Diabetes Therapy, April 2014, Springer Science + Business Media

    Dr Sylvie Dejager

  11. Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan

    Article • Vascular Health and Risk Management, December 2013, Taylor & Francis

    Dr Sylvie Dejager

  12. Results of the Post-Marketing Survey of Vildagliptin in France

    Article • Value in Health, November 2013, Elsevier

    Mr Stéphane Quéré, Dr Sylvie Dejager

  13. Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes: Is this of concern?

    Article • Diabetes Care, October 2013, American Diabetes Association

    Dr Sylvie Dejager

  14. Modalités de dépistage de la maladie rénale chronique dans une cohorte française de patients diabétiques de type 2 : étude OréDia

    Article • Néphrologie & Thérapeutique, September 2013, Elsevier

    Mr Stéphane Quéré, Dr Sylvie Dejager

  15. Prise en charge thérapeutique globale de patients diabétiques de type 2 avec ou sans maladie rénale chronique : étude OréDia

    Article • Néphrologie & Thérapeutique, September 2013, Elsevier

    Mr Stéphane Quéré, Dr Sylvie Dejager

  16. Comment sont pris en charge en France en 2012 les patients diabétiques de type 2 avec maladie rénale chronique ? Étude OreDia

    Article • Annales d Endocrinologie, September 2013, Elsevier

    Dr Sylvie Dejager

  17. Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study

    Article • Diabetes Therapy, August 2013, Springer Science + Business Media

    Mr Stéphane Quéré, Dr Sylvie Dejager

  18. Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment

    Article • Diabetes Therapy, July 2013, Springer Science + Business Media

    Dr Sylvie Dejager

  19. Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2 Diabetes Mellitus: What Is the Evidence?

    Article • Hospital Practice, April 2013, Taylor & Francis

    Dr Sylvie Dejager

  20. P1053 Impact du phénomène de l’aube sur l’exposition au glucose dans le diabète de type 2

    Article • Diabetes & Metabolism, March 2013, Elsevier

    Dr Sylvie Dejager

  21. Add-On Therapies to Metformin in Type 2 Diabetes: What Modulates the Respective Decrements in Postprandial and Basal Glucose?

    Article • Diabetes Technology & Therapeutics, October 2012, Mary Ann Liebert Inc

    Dr Sylvie Dejager

  22. Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin

    Article • Diabetes Therapy, June 2012, Springer Science + Business Media

    Dr Sylvie Dejager

  23. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

    Article • Vascular Health and Risk Management, May 2012, Taylor & Francis

    Dr James E Foley, Dr Sylvie Dejager

  24. Incretin Therapies in the Management of Patients with Type 2 Diabetes Mellitus and Renal Impairment

    Article • Hospital Practice, April 2012, Taylor & Francis

    Dr Sylvie Dejager

  25. P90 Critères de choix d’une bithérapie dans une population diabétique âgée traitée par metformine : étude HYPOCRAS, données d’inclusion.

    Article • Diabetes & Metabolism, March 2012, Elsevier

    Mr Stéphane Quéré, Dr Sylvie Dejager

  26. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

    Article • Diabetes Obesity and Metabolism, July 2011, Wiley

    Dr Sylvie Dejager

  27. Exercise in the Management of Type 2 Diabetes Mellitus: What are the Benefits and how does it Work?

    Article • The Physician and Sportsmedicine, May 2011, Taylor & Francis

    Dr Sylvie Dejager

  28. Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management

    Article • Diabetes Therapy, February 2011, Springer Science + Business Media

    Dr Sylvie Dejager

  29. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

    Article • Vascular Health and Risk Management, February 2011, Taylor & Francis

    Dr James E Foley, Dr Sylvie Dejager

  30. Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus

    Article • Hospital Practice, February 2011, Taylor & Francis

    Dr Sylvie Dejager

  31. GLP-1: What is known, new and controversial in 2010?

    Article • Diabetes & Metabolism, December 2010, Elsevier

    Dr Sylvie Dejager

  32. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly

    Article • Current Medical Research and Opinion, May 2010, Informa Healthcare

    Dr Sylvie Dejager

  33. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial

    Article • Diabetes Obesity and Metabolism, August 2009, Wiley

    Dr Sylvie Dejager

  34. Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2009, Endocrine Society

    Dr Sylvie Dejager

  35. O30 Vildagliptine améliore la sensibilité au glucose des cellules chez les patients diabétiques de type 2 : réponse du glucagon à l’hypoglycémie

    Article • Diabetes & Metabolism, March 2009, Elsevier

    Dr Sylvie Dejager

  36. Association gliptines et sulfamides hypoglycémiants

    Article • Médecine des Maladies Métaboliques, December 2008, Elsevier

    Dr Sylvie Dejager

  37. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy

    Article • Pharmacogenomics, September 2008, Future Medicine

    Dr Sylvie Dejager

  38. P74 La vildagliptine est efficace et bien tolérée lorsqu’elle est ajoutée à un sulfamide hypoglycémiant chez des patients diabétiques de type 2

    Article • Diabetes & Metabolism, March 2008, Elsevier

    Dr Sylvie Dejager

  39. O5 La vildagliptine améliore la fonction cellulaire chez des patients diabétiques de type 2 : analyse des données poolées en monothérapie

    Article • Diabetes & Metabolism, March 2008, Elsevier

    Dr Sylvie Dejager

  40. O6 Efficacité et tolérance de la vildagliptine chez le sujet âgé : analyse poolée des études menées en monothérapie

    Article • Diabetes & Metabolism, March 2008, Elsevier

    Dr Sylvie Dejager

  41. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

    Article • Diabetes Research and Clinical Practice, April 2007, Elsevier

    Dr Sylvie Dejager

  42. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

    Article • Diabetologia, March 2007, Springer Science + Business Media

    Dr Sylvie Dejager

  43. Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study

    Article • Hormone and Metabolic Research, March 2007, Thieme Publishing Group

    Dr Sylvie Dejager

  44. Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: A 24-week, double-blind, randomized trial

    Article • Diabetes Care, January 2007, American Diabetes Association

    Dr Sylvie Dejager

  45. Diabè;te insipide central

    Article • EMC - Traité de médecine AKOS, January 2006, Elsevier

    Dr Sylvie Dejager

  46. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study

    Article • Cardiovascular Drugs and Therapy, December 2005, Springer Science + Business Media

    Dr Sylvie Dejager

  47. Comparison of Efficacy and Safety Assessment of Fluvastatin in Patients <65 Years Versus ≥65 Years of Age

    Article • The American Journal of Cardiology, October 2005, Elsevier

    Dr Sylvie Dejager

  48. W05-O-001 Genetic polymorphism in the organic anion transporter polypeptide-C gene: A determinant factor in statin response?

    Article • Atherosclerosis Supplements, April 2005, Elsevier

    Dr Sylvie Dejager

  49. Étude pacifique : postangioplastie coronaire en France et intervention thérapeutique

    Article • Annales de Cardiologie et d Angéiologie, November 2004, Elsevier

    Dr Sylvie Dejager

  50. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)

    Article • The American Journal of Cardiology, October 2003, Elsevier

    Dr Sylvie Dejager

  51. A Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering Drugs

    Article • Cardiovascular Drugs and Therapy, September 2003, Springer Science + Business Media

    Dr Sylvie Dejager

  52. Short-Term Efficacy and Safety of Extended-Release Fluvastatin in a Large Cohort of Elderly Patients

    Article • The American Journal of Geriatric Cardiology, July 2003, Wiley

    Dr Sylvie Dejager

  53. Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly Patients

    Article • The American Journal of Geriatric Cardiology, July 2003, Wiley

    Dr Sylvie Dejager

  54. 2P-0578 Combination of fluvastatin and fibrates: Effects of baseline triglycerides on changes in lipid profile

    Article • Atherosclerosis Supplements, January 2003, Elsevier

    Dr Sylvie Dejager

  55. A Comprehensive Endocrine Description of Kennedy's Disease Revealing Androgen Insensitivity Linked to CAG Repeat Length

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2002, Endocrine Society

    Dr Sylvie Dejager

  56. Diabetes ins?pida central

    Article • EMC - Tratado de Medicina, January 2001, Elsevier

    Dr Sylvie Dejager

  57. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia

    Article • The American Journal of Cardiology, January 2000, Elsevier

    Dr Sylvie Dejager

  58. Relationship between Triglycerides and Factor VIIc and Plasminogen Activator Inhibitor Type-1

    Article • Thrombosis Research, November 1999, Elsevier

    Dr Sylvie Dejager

  59. Sheehan's syndrome: differential diagnosis in the acute phase

    Article • Journal of Internal Medicine, September 1998, Wiley

    Dr Sylvie Dejager

  60. Pharmacologic modulation of the atherogenic LDL profile in dyslipidemia

    Article • Atherosclerosis, September 1994, Elsevier

    Dr Sylvie Dejager

  61. Dominant negative mutations of the scavenger receptor. Native receptor inactivation by expression of truncated variants.

    Article • Journal of Clinical Investigation, August 1993, American Society for Clinical Investigation

    Dr Sylvie Dejager

  62. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia

    Article • Atherosclerosis, April 1993, Elsevier

    Dr Sylvie Dejager

  63. Oxidized low density lipoproteins bind to the scavenger receptor expressed by rabbit smooth muscle cells and macrophages

    Article • Arteriosclerosis Thrombosis and Vascular Biology, March 1993, Wolters Kluwer Health

    Dr Sylvie Dejager

  64. Further characterization of the acetyl LDL (scavenger) receptor expressed by rabbit smooth muscle cells and fibroblasts

    Article • Arteriosclerosis Thrombosis and Vascular Biology, November 1992, Wolters Kluwer Health

    Dr Sylvie Dejager

  65. The Muir-Torre Syndrome: A Disease of Sebaceous and Colonic Neoplasms

    Article • Dermatology, January 1989, Karger Publishers

    Dr Sylvie Dejager